publications-banner

Information about pipeline products

PublicationView

Other/Multi
Breast Cancer
A retrospective study of do-not-do practice recommendations in metastatic breast cancer in Spain
Vega IG-C, Rescalvo MAG, Moreno F, et al.
Revista de Senología y Patología Mamaria 2024;37 doi.org/10.1016/j.senol.2024.100593
Edoxaban
Cardiovascular - AF
Pharmacokinetics of edoxaban 15 mg in very elderly patients with nonvalvular atrial fibrillation: A subanalysis of the ELDERCARE-AF study
Yamashita T, Igawa Y, Fukuzawa M, et al.
Thromb Haemost. 2024. doi: 10.1055/s-0044-1785511. Epub ahead of print.
Edoxaban
Breast Cancer Cardiovascular - AF
Venous thromboembolism in Japanese patients with breast cancer: Subgroup analysis of the Cancer-VTE registry
Ohsumi S, Watanabe K, Kondo N, et al.
Breast Cancer. 2023;30(4):607-616.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in breast cancer
Martín M, Pandiella A, Vargas-Castrillón E, et al.
Crit Rev Oncol Hematol. 2024;198:104355. doi: 10.1016/j.critrevonc.2024.104355. Epub ahead of print.
Other/Multi
Gastric Cancer
Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany
Luna J, Picker N, Wilke T, et al.
BMC Cancer. 2024;24(1):462.
T-DXd
Breast Cancer
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
Guarneri V, Coelho JLP, Duhoux FP, et al.
Future Oncol. 2024. doi: 10.2217/fon-2024-0015. Epub ahead of print.
Edoxaban
Cardiovascular - AF
Impact of frailty in patients with non-valvular atrial fibrillation undergoing catheter ablation
Soejima K, Nogami A, Kumagai K, et al.
J Arrhythmia. 2024;40(3):463-471.
Pexidartinib
Other/Multi
Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor
Lin F, Kwong WJ, Pan I, et al.
Oncologist. 2024;29(4):e535-e543.
Other/Multi
Lung Cancer
Augmenting external control arms using Bayesian borrowing: A case study in first-line non-small cell lung cancer
Struebing A, McKibbon C, Ruan H, et al.
J Comp Eff Res. 2024 May;13(5):e230175.
Valemetostat
Other/Multi
Effective in vitro evaluation of the risk of histamine release related to valemetostat tosylate using MRGPRX2-expressing cells
Hamamura-Yasuno E, Kinoshita J, Goto K, et al.
J Toxicol Sci. 2024;49(4):163-174.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer